These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18978520)

  • 1. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.
    Watanabe J; Suzuki Y; Fukui N; Sugai T; Ono S; Inoue Y; Someya T
    Ther Drug Monit; 2008 Dec; 30(6):705-8. PubMed ID: 18978520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics.
    Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Psychopharmacol; 2011 Jul; 25(7):908-14. PubMed ID: 20547595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.
    Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
    Eur J Clin Pharmacol; 2003 Feb; 58(10):659-61. PubMed ID: 12610741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(2):285-8. PubMed ID: 20118554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The major fluvoxamine metabolite in urine is formed by CYP2D6.
    Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.
    Sugahara H; Maebara C; Ohtani H; Handa M; Ando K; Mine K; Kubo C; Ieiri I; Sawada Y
    Eur J Clin Pharmacol; 2009 Jul; 65(7):699-704. PubMed ID: 19225771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Ther Drug Monit; 2003 Aug; 25(4):463-8. PubMed ID: 12883230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
    Sawamura K; Suzuki Y; Someya T
    Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
    Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L
    Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
    Carrillo JA; Ramos SI; Herraiz AG; Llerena A; Agundez JA; Berecz R; Duran M; Benítez J
    J Clin Psychopharmacol; 1999 Dec; 19(6):494-9. PubMed ID: 10587283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles.
    Suzuki Y; Shioiri T; Muratake T; Kawashima Y; Sato S; Hagiwara M; Inoue Y; Shimoda K; Someya T
    Eur J Clin Pharmacol; 2003 Apr; 58(12):829-33. PubMed ID: 12698310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.